Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash

But the Moderna story dimmed in recent years as demand for coronavirus vaccines declined, and as a result, earnings sank. On top of this, investors grew to think of Moderna as a "coronavirus vaccine stock," and therefore considered that this growth story was over as of later pandemic days. Though Moderna has a broad pipeline of candidates across therapeutic areas, the company still is having trouble renewing its identity. Maker of a top-selling product The company I'm talking about is Moderna (MRNA -2.32%), ...